A Phase 4 interventional study of Trifarotene Cream and Trifarotene Vehicle Cream in Acne Vulgaris, sponsored by Galderma R&D. Completed at 18 sites in 3 countries. Open to participants aged 17 Years to 35 Years. Per ClinicalTrials.gov, last updated 2024-06-11.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing trifarotene in Acne Vulgaris — none open to participants now, 1 under way, 1 of them phase 3. trifarotene · Acne Vulgaris.
Among the 12 studies testing trifarotene in Acne Vulgaris, this one is the 11th largest by enrollment, is one of 2 that started in 2021, is one of 3 in phase 4, and was the 7th registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →None of the 12 studies testing trifarotene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →
trifarotene: first FDA approval 2019 (AKLIEF). What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 17 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2021.
This study's enrollment of 121 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 507 across the 12 interventional studies. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 3 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
49 studies in Acne Vulgaris by Galderma Group AG: none open now, 1 under way, 1 of them phase 3. Of 48 finished, 39 (81%) have results posted.
Among the 49 studies in Acne Vulgaris by Galderma Group AG, this one is the 28th largest by enrollment of the 46 interventional ones that give a count, is one of 2 that started in 2021, is one of 20 in phase 4, and was the 47th registered.
Galderma Group AG’s Acne Vulgaris studies by the year they started, since 2004.
1 of the studies testing trifarotene in Acne Vulgaris that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186413Phase 3Galderma R&DA Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing trifarotene in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 49 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle on the risk of formation of atrophic acne scars after 24 weeks of treatment in facial acne participants assessed by atrophic acne scars count.
Key Inclusion Criteria:
Participant with clinical diagnosis of acne vulgaris on the face as defined by (excluding the nose and middle zone of approximately 2 centimeter [cm]):
Participant with a symmetrical number of the following lesions/scars on the whole face:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Trifarotene Vehicle Cream
Drug: Trifarotene Cream
Participants will apply a thin a layer of trifarotene (CD5789) 50 mcg/g cream to the face once daily, in the evening for 24 weeks
Also known as: AKLIEF®
Participants will apply a thin a layer of trifarotene vehicle cream to the face once daily, in the evening for 24 weeks
Absolute Change From Baseline in Total Atrophic Acne Scar Count Per Half Face at Week 24
The scars were counted according to their size defined in two categories using 2 millimeter (mm) and 4 mm punch biopsy tools for size classification: 1) atrophic scars 2 to 4 mm: included boxcar (sheer edges), rolling (irregular surface), and undetermined types; 2) atrophic scars greater than (\>) 4 mm: included boxcar (sheer edges), rolling (irregular surface), and undetermined types. Each type of atrophic acne scar was counted separately for each half-face by the evaluator for following regions: right forehead, right cheek, right side of the chin, left forehead, left cheek and left side of the chin. To obtain the total number of atrophic scars per half-face, atrophic acne scar counts for each half-face was added.
Time frame: Baseline, Week 24
Absolute Change From Baseline in Total Atrophic Acne Scar Count Per Half-Face up to Week 20
The scars were counted according to their size defined in two categories using 2 mm and 4 mm punch biopsy tools for size classification: 1) atrophic scars 2 to 4 mm: included boxcar (sheer edges), rolling (irregular surface), and undetermined types; 2) atrophic scars \> 4 mm: included boxcar (sheer edges), rolling (irregular surface), and undetermined types. Each type of atrophic acne scar was counted separately for each half-face by the evaluator for following regions: right forehead, right cheek, right side of the chin, left forehead, left cheek and left side of the chin. To obtain the total number of atrophic scars per half-face, atrophic acne scar counts for each half-face was added.
Time frame: Baseline, up to Week 20
The study was conducted at 20 sites in the United States, Canada, and France.
| Milestone | Trifarotene 50mcg/g Cream | Trifarotene Vehicle Cream |
|---|---|---|
| Started | 121 | 121 |
| Completed | 99 | 99 |
| Not completed | 22 | 22 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Withdrawal by subject | 13 | 13 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Non-compliance with study drug | 1 | 1 |
| Withdrew: Lost to follow-up | 4 | 4 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Protocol violation | 1 | 1 |
The scars were counted according to their size defined in two categories using 2 millimeter (mm) and 4 mm punch biopsy tools for size classification: 1) atrophic scars 2 to 4 mm: included boxcar (sheer edges), rolling (irregular surface), and undetermined types; 2) atrophic scars greater than (\>) 4 mm: included boxcar (sheer edges), rolling (irregular surface), and undetermined types. Each type of atrophic acne scar was counted separately for each half-face by the evaluator for following regions: right forehead, right cheek, right side of the chin, left forehead, left cheek and left side of the chin. To obtain the total number of atrophic scars per half-face, atrophic acne scar counts for each half-face was added.
| atrophic acne scars | Trifarotene 50mcg/g Cream | Trifarotene Vehicle Cream |
|---|---|---|
| Absolute Change From Baseline in Total Atrophic Acne Scar Count Per Half Face at Week 24 | -5.9 ± 0.51 | -2.7 ± 0.37 |
The scars were counted according to their size defined in two categories using 2 mm and 4 mm punch biopsy tools for size classification: 1) atrophic scars 2 to 4 mm: included boxcar (sheer edges), rolling (irregular surface), and undetermined types; 2) atrophic scars \> 4 mm: included boxcar (sheer edges), rolling (irregular surface), and undetermined types. Each type of atrophic acne scar was counted separately for each half-face by the evaluator for following regions: right forehead, right cheek, right side of the chin, left forehead, left cheek and left side of the chin. To obtain the total number of atrophic scars per half-face, atrophic acne scar counts for each half-face was added.
| atrophic acne scars | Trifarotene 50mcg/g Cream | Trifarotene Vehicle Cream |
|---|---|---|
| Change at Week 1 | -0.3 ± 0.21 | -0.3 ± 0.16 |
| Change at Week 2 | -0.9 ± 0.26 | -0.4 ± 0.11 |
| Change at Week 4 | -1.5 ± 0.27 | -0.7 ± 0.18 |
| Change at Week 8 | -2.5 ± 0.30 | -1.1 ± 0.30 |
| Change at Week 12 | -3.8 ± 0.37 | -1.7 ± 0.32 |
| Change at Week 16 | -4.4 ± 0.40 | -1.7 ± 0.47 |
| Change at Week 20 | -5.0 ± 0.47 | -2.5 ± 0.33 |
Collected over From screening up to Week 28. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Trifarotene 50mcg/g Cream | 0/121 (0%) | 0/121 (0%) | 7/121 (5.8%) |
| Trifarotene Vehicle Cream | 0/121 (0%) | 0/121 (0%) | 3/121 (2.5%) |
| All Acne Vulgaris Participants | 0/121 (0%) | 0/121 (0%) | 33/121 (27.3%) |
| Event | Trifarotene 50mcg/g Cream | Trifarotene Vehicle Cream | All Acne Vulgaris Participants |
|---|---|---|---|
| COVID-19Infections and infestations | 0/121 | 0/121 | 10/121 |
| NasopharyngitisInfections and infestations | 0/121 | 0/121 | 2/121 |
| PruritusSkin and subcutaneous tissue disorders | 1/121 | 1/121 | 2/121 |
| RashSkin and subcutaneous tissue disorders | 1/121 | 0/121 | 2/121 |
| Skin tightnessSkin and subcutaneous tissue disorders | 2/121 | 1/121 | 2/121 |
| Skin lacerationInjury, poisoning and procedural complications | 1/121 | 1/121 | 2/121 |
| SARS-CoV-2 test positiveInvestigations | 0/121 | 0/121 | 2/121 |
| Gastroenteritis viralInfections and infestations | 0/121 | 0/121 | 1/121 |
| Kidney infectionInfections and infestations | 0/121 | 0/121 | 1/121 |
| Tooth abscessInfections and infestations | 0/121 | 0/121 | 1/121 |
Intent to treat (ITT) population included all randomized partcipants.
| Age, Continuous(years) | All Acne Vulgaris Participants |
|---|---|
| Mean | 22.9 ± 5.12 |
| Sex: Female, Male(Participants) | All Acne Vulgaris Participants |
|---|---|
| Female | 88 |
| Male | 33 |
| Ethnicity (NIH/OMB)(Participants) | All Acne Vulgaris Participants |
|---|---|
| Hispanic or Latino | 26 |
| Not Hispanic or Latino | 95 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | All Acne Vulgaris Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 12 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 9 |
| White | 97 |
| More than one race | 0 |
| Unknown or Not Reported | 3 |
| Region of Enrollment(count of participants) | All Acne Vulgaris Participants |
|---|---|
| Canada | 9 |
| United States | 110 |
| France | 2 |
| Fitzpatrick Skin Type(Participants) | All Acne Vulgaris Participants |
|---|---|
| Type I | 7 |
| Type II | 43 |
| Type III | 31 |
| Type IV | 26 |
| Type V | 11 |
| Type VI | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2021 to primary completion in Feb 2023, 20 months.
Results were first posted in Jun 2024, 1 year 4 months after primary completion.
Of 45 phase 4 interventional studies under Acne Vulgaris, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 20 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trifarotene